Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis.
Low S, Wu H, Jerath K, Tibolla A, Fogal B, Conrad R, MacDougall M, Kerr S, Berger V, Dave R, Villalona J, Pantages L, Ahlberg J, Li H, Van Hoorick D, Ververken C, Broadwater J, Waterman A, Singh S, Kroe-Barrett R. Low S, et al. Among authors: macdougall m. MAbs. 2020 Jan-Dec;12(1):1709322. doi: 10.1080/19420862.2019.1709322. MAbs. 2020. PMID: 31924119 Free PMC article.
Non-neutralizing antibodies increase endogenous circulating Ang1 levels.
Zheng C, Toth J, Bigwarfe T, MacDougall M, Jerath K, Bovat K, Smith J, Sun P, Hayes D, Fryer R, Singh S, Kroe-Barrett R. Zheng C, et al. Among authors: macdougall m. MAbs. 2018 Nov-Dec;10(8):1260-1268. doi: 10.1080/19420862.2018.1521130. Epub 2018 Nov 7. MAbs. 2018. PMID: 30199300 Free PMC article.
Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese Mice.
Sun P, Bartlett CS, Zheng C, Bigwarfe T, Grant JM, MacDougall M, Berger V, Kerr S, Qian HS, McHugh M, Chen H, Zhang X, Carpenter ML, Robinson HN, Miglietta J, Lamla T, Fryer RM. Sun P, et al. Among authors: macdougall m. J Pharmacol Exp Ther. 2022 Sep;382(3):266-276. doi: 10.1124/jpet.121.001067. Epub 2022 Jul 2. J Pharmacol Exp Ther. 2022. PMID: 35779860
Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists.
Ladouceur GH, Cook JH, Hertzog DL, Jones JH, Hundertmark T, Korpusik M, Lease TG, Livingston JN, MacDougall ML, Osterhout MH, Phelan K, Romero RH, Schoen WR, Shao C, Smith RA. Ladouceur GH, et al. Among authors: macdougall ml. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3421-4. doi: 10.1016/s0960-894x(02)00736-9. Bioorg Med Chem Lett. 2002. PMID: 12419375
Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis.
Smith RA, Hertzog DL, Osterhout MH, Ladouceur GH, Korpusik M, Bobko MA, Jones JH, Phelan K, Romero RH, Hundertmark T, MacDougall ML, Livingston JN, Schoen WR. Smith RA, et al. Among authors: macdougall ml. Bioorg Med Chem Lett. 2002 May 6;12(9):1303-6. doi: 10.1016/s0960-894x(02)00143-9. Bioorg Med Chem Lett. 2002. PMID: 11965376
319 results